Jeff Sternlicht: The Most Powerful Time to Lower Cholesterol Is Before Anyone Thinks You Need It
Jeff Sternlicht, Emergency Physician and Medical Director at Vituity, shared a post on LinkedIn about a recent article by Dinesh K. Kalra et al, published in Journal of Clinical Lipidology:
“The Most Powerful Time to Lower Cholesterol
Is Before Anyone Thinks You Need It
We often think cholesterol treatment works best after someone already has heart disease.
But a new meta-analysis published in the Journal of Clinical Lipidology suggests something surprising.
Lowering LDL cholesterol may actually reduce cardiovascular risk even more in primary prevention than in secondary prevention.
Across pooled randomized trials, each 1 mmol/L (≈39 mg/dL) reduction in LDL was associated with about a 30% reduction in major cardiovascular events.
That relative risk reduction is greater than what is typically seen in secondary prevention populations.
Why would that be?
Because atherosclerosis is a lifetime exposure disease.
Plaque does not suddenly appear the day before a heart attack.
It builds quietly over decades as ApoB-containing lipoproteins circulate through the arteries.
Lowering LDL later in life can help stabilize plaque that already exists.
Lowering LDL earlier in life can prevent much of that plaque from forming in the first place.
Those are two very different biological situations.
Two people can have the same LDL today.
One spent 40 years with LDL around 160.
The other spent 40 years closer to 80.
Their arteries are not the same.
This is why modern cardiovascular risk reduction is increasingly focused on earlier detection and earlier action.
Look for plaque earlier.
Identify hidden risk.
Lower lifetime ApoB exposure.
The goal is not just treating heart disease.
The goal is preventing the first heart attack entirely.
Disclaimer: Views are my own. This post is for educational purposes only and is not medical advice.”
Title: Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials: A meta-analysis
Authors: Dinesh K. Kalra, Kausik K. Ray, Archna Bajaj, Pamela R. Kushner, Meredith L. Wilcox, Mary R. Dicklin, Carol F. Kirkpatrick, Kevin C. Maki
Read the Full Article on Journal of Clinical Lipidology
Stay updated with Hemostasis Today.
-
Jun 24, 2026, 16:32Arlindo Nascimento de Lemos Junior: Thrombus Echogenicity as a Predictor of Post-Thrombotic Syndrome Severity After DVT
-
Jun 24, 2026, 16:09Jimi Olaghere: The Future of Sickle Cell Disease Research Starts With Collaboration
-
Jun 24, 2026, 16:03Von Willebrand Disease as a Common Yet Under-Recognised Bleeding Disorder – EHC
-
Jun 24, 2026, 15:57Maia Meier: Women with Bleeding Disorders Reach the Summit of Mont Blanc
-
Jun 24, 2026, 15:40Annette Bowyer: The Emerging Role of Extravascular Factor VII in Haemostasis
-
Jun 24, 2026, 13:50Tijjani Balas: Why Early Detection of DVT Matters
-
Jun 24, 2026, 13:43Brandon Michael Henry: Interpreting Complement Activation After AAV Gene Therapy
-
Jun 24, 2026, 13:37Heba Youssef: Heparin-Induced Thrombocytopenia – The Prothrombotic Emergency You Cannot Miss
-
Jun 24, 2026, 13:32Jecko Thachil: Understanding the Clinical Spectrum of Vitamin B12